Duduyemi Oladimeji Paul, Potapenko Kateryna, Limanska Nataliia, Kotsyuda Sofiya, Petriv Nataliia, Suo Huizhen, Gudzenko Tetyana, Ivanytsia Volodymyr, Yevsa Tetyana
Department of Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hanover, Germany.
Department of Microbiology, Virology, and Biotechnology, Odesa I. I. Mechnykov National University, Odesa, Ukraine.
Front Microbiol. 2024 Nov 11;15:1451170. doi: 10.3389/fmicb.2024.1451170. eCollection 2024.
Primary liver cancer (PLC), comprising hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), is a severe form of cancer associated with a high mortality and morbidity rate and increasing incidence worldwide. Current treatment options are limited and chemotherapeutics demonstrate strong side effects. New therapies are highly required. Lactobacilli represent the most diverse lactic acid-producing bacteria group and a prominent example of probiotics. Several studies have highlighted the anticancer efficacy of probiotics, especially of . However, there are limited studies on its activity on two PLC types, hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). This study evaluated the inhibitory mechanism and properties of ONU 12 (Lp 12) and ONU 355 (Lp 355), isolated from grapes in Ukraine and France, in murine PLC cell lines, Strain ATCC 393 (Lc 393) has been taken for a direct comparison, as the most studied probiotic strain. The three species were used in three forms: as live and heat-killed suspensions, and as sonicated extracts, and tested either as a monotherapy or in combination with standard chemotherapeutics (sorafenib for HCC and gemcitabine for CCA). Cell proliferation and viability were assessed via crystal violet staining assay and cell counting kit-8 assay. The induction of senescence was investigated by senescence-associated β-galactosidase assay. Fluorescence-activated cell sorting analysis was used to determine the apoptotic mechanism behind the inhibitory property of lactobacilli. The results showed that the live suspensions and sonicated extracts of Lp 12, Lp 355, and Lc 393 demonstrated inhibitory properties in CCA and HCC cells after 48 h of incubation. In combinations with standard chemotherapeutics, lactobacilli treatments have shown strong synergistic effects. The combination therapy allowed to reduce the chemotherapeutic doses of gemcitabine from 50 μM to 0.1 and 0.05 μM and sorafenib from 13.8 μM to 6.9 and 3.45 μM. Successful treatment regimes induced early apoptosis and cellular senescence in PLC, as the mechanism of inhibition. Heat-killed suspensions showed no inhibitory effect in none of the cell lines. Both strains, Lp 12 and Lp 355, showed successful results and need further testing , using autochthonous HCC and CCA models.
原发性肝癌(PLC),包括肝细胞癌(HCC)和胆管癌(CCA),是一种严重的癌症形式,在全球范围内死亡率和发病率都很高且发病率不断上升。目前的治疗选择有限,化疗药物有很强的副作用。非常需要新的治疗方法。乳酸杆菌是最多样化的产乳酸菌群,也是益生菌的一个突出例子。几项研究强调了益生菌的抗癌功效,尤其是……然而,关于其对肝细胞癌(HCC)和胆管癌(CCA)这两种PLC类型活性的研究有限。本研究评估了从乌克兰和法国葡萄中分离出的ONU 12(Lp 12)和ONU 355(Lp 355)在小鼠PLC细胞系中的抑制机制和特性,以研究最多的益生菌菌株嗜热栖热放线菌ATCC 393(Lc 393)作为直接对照。这三种乳酸杆菌以三种形式使用:活菌悬液、热灭活悬液和超声提取物,并作为单一疗法或与标准化疗药物(用于HCC的索拉非尼和用于CCA的吉西他滨)联合进行测试。通过结晶紫染色试验和细胞计数试剂盒 - 8试验评估细胞增殖和活力。通过衰老相关β - 半乳糖苷酶试验研究衰老的诱导情况。使用荧光激活细胞分选分析来确定乳酸杆菌抑制特性背后的凋亡机制。结果表明,在孵育48小时后,Lp 12、Lp 355和Lc 393的活菌悬液和超声提取物在CCA和HCC细胞中均表现出抑制特性。与标准化疗药物联合使用时,乳酸杆菌治疗显示出很强的协同作用。联合治疗使吉西他滨的化疗剂量从50μM降至0.1μM和0.05μM,索拉非尼的剂量从13.8μM降至6.9μM和3.45μM。成功的治疗方案诱导PLC早期凋亡和细胞衰老,作为抑制机制。热灭活悬液在所有细胞系中均未显示出抑制作用。Lp 12和Lp 355这两种菌株均取得了成功结果,需要使用本地的HCC和CCA模型进行进一步测试。